Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
Conditions: Head & Neck Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Colorectal Cancer; Endometrial Cancer; Urothelial Carcinoma (UC); Breast Cancer

Interventions: Drug: STRO-006; Drug: Pembrolizumab

Sponsors: Sutro Biopharma, Inc.

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 9, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments